Health & Environmental Research Online (HERO)


Print Feedback Export to File
2851018 
Journal Article 
Perfluorononanoic acid in combination with 14 chemicals exerts low-dose mixture effects in rats 
Hadrup, N; Pedersen, M; Skov, K; Hansen, NL; Berthelsen, LO; Kongsbak, K; Boberg, J; Dybdahl, M; Hass, U; Frandsen, H; Vinggaard, AM 
2016 
Yes 
Archives of Toxicology
ISSN: 0340-5761
EISSN: 1432-0738 
90 
661-675 
English 
Humans are simultaneously exposed to several chemicals that act jointly to induce mixture effects. At doses close to or higher than no-observed adverse effect levels, chemicals usually act additively in experimental studies. However, we are lacking knowledge on the importance of exposure to complex real-world mixtures at more relevant human exposure levels. We hypothesised that adverse mixture effects occur at doses approaching high-end human exposure levels. A mixture (Mix) of 14 chemicals at a combined dose of 2.5 mg/kg bw/day was tested in combination with perfluorononanoic acid (PFNA) at doses of 0.0125 (Low PFNA), 0.25 (Mid PFNA) and 5 (High PFNA) mg/kg bw/day by oral administration for 14 days in juvenile male rats. Indication of a toxicokinetic interaction was found, as simultaneous exposure to PFNA and the Mix caused a 2.8-fold increase in plasma PFNA concentrations at Low PFNA. An increase in testosterone and dihydrotestosterone plasma concentrations was observed for Low PFNA + Mix. This effect was considered non-monotonic, as higher doses did not cause this effect. Reduced LH plasma concentrations together with increased androgen concentrations indicate a disturbed pituitary-testis axis caused by the 15-chemical mixture. Low PFNA by itself increased the corticosterone plasma concentration, an effect which was normalised after simultaneous exposure to Mix. This combined with affected ACTH plasma concentrations and down-regulation of 11β HSD mRNA in livers indicates a disturbed pituitary-adrenal axis. In conclusion, our data suggest that mixtures of environmental chemicals at doses approaching high-end human exposure levels can cause a hormonal imbalance and disturb steroid hormones and their regulation. These effects may be non-monotonic and were observed at low doses. Whether this reflects a more general phenomenon that should be taken into consideration when predicting human mixture effects or represents a rarer phenomenon remains to be shown. 
Mixture toxicology; Steroidogenesis; Testosterone; Corticosterone; Pituitary hormones; Perfluorononanoic acid (PFNA) 
• SR Automation
PFAS
• Additional PFAS (formerly XAgency)
     Literature Search November 2019
          Other Sources
               ATSDR
               TEDX
     Screened Studies
          Excluded
               Exclude (TIAB)
• Expanded PFAS SEM (formerly PFAS 430)
     Litsearch: September 2019
          Other Sources
               PFAS TOX Database
     Screened Studies
          Excluded
               Exclude (TIAB)
• ^Per- and Polyfluoroalkyl Substances (PFAS)
     PFOA (335-67-1) and PFOS (1763-23-1)
          Literature Search – Adverse outcome pathway (2015-present)
               WOS
     PFNA (375-95-1)
          Literature Search
               Pubmed
               WOS
• PFAS 150
     Literature Search August 2019
          PubMed
          Web of Science
          Other sources
               PFAS TOX Database
     Not prioritized for screening
     Perfluorononanoic acid
• PFBA
     Protocol References
• PFNA
     Literature Search (August 2017)
          Pubmed
     Litsearch Update 2017-2018
          Toxline
     Litsearch Addl Synonyms 2018
          Toxline
          WOS
     PFNA Literature Search pre-2019
          Pubmed
          WOS
     Literature Search
          Additional Strategies
          ATSDR
          Pubmed
          Toxline
          WOS
     Screening Results
          Excluded/Not on Topic
     Title and Abstract Screening
          Full Text Screening
               Studies Meeting PECO
                    Animal health effects studies
     June 2022 Pelch Database
     June 2022 PFAS150
• PFOA (335-67-1) and PFOS (1763-23-1)
     Literature Search – Adverse outcome pathway (2015-present)
          WOS
     Screening Results
          Excluded/Not on Topic